RSS-Feed abonnieren
DOI: 10.1055/s-0043-1770100
Risk of Bleeding in Liver Cirrhosis Receiving Direct Oral Anticoagulants: A Systematic Review and Meta-analysis
![](https://www.thieme-connect.de/media/10.1055-s-00035024/202311/lookinside/thumbnails/10-1055-s-0043-1770100_23030096-1.jpg)
Abstract
Background Direct oral anticoagulants (DOACs) are effective for the management of thromboembolic disorders. However, bleeding remains a major concern in cirrhotic patients receiving DOACs.
Methods PubMed, EMBASE, and Cochrane Library databases were searched. The incidence of bleeding episodes in cirrhotic patients receiving DOACs was pooled. Odds ratios (ORs) were calculated to compare the incidence of bleeding episodes in cirrhotic patients who received DOACs versus those who received conventional anticoagulants and did not receive anticoagulants.
Results Twenty-nine studies were included. All bleeding, major bleeding, fatal bleeding, gastrointestinal bleeding, and intracranial hemorrhage episodes were observed in 310/2,469, 100/1,388, 2/611, 166/1,886, and 5/1,147 cirrhotic patients receiving DOACs, respectively. Their pooled incidences were 13, 6, 0, 8, and 0%, respectively. They became higher in subgroup analyses of studies with advanced age, a longer treatment duration, and Child–Turcotte–Pugh class C. Compared with conventional anticoagulants, DOACs were associated with lower incidences of all bleeding (OR = 0.71, 95% confidence interval [CI] = 0.52–0.98) and major bleeding (OR = 0.55, 95% CI = 0.37–0.83) in cirrhotic patients, but not those of fatal bleeding (OR = 0.21, 95% CI = 0.04–1.28), gastrointestinal bleeding (OR = 0.78, 95% CI = 0.52–1.17), or intracranial hemorrhage (OR = 0.36, 95% CI = 0.12–1.12). The incidences of all bleeding (OR = 1.04, 95% CI = 0.22–4.79) and major bleeding (OR = 0.96, 95% CI = 0.26–3.61) did not significantly differ between cirrhotic patients with portal vein thrombosis (PVT) who received DOACs and those who did not receive anticoagulants.
Conclusion DOACs carry a low risk of bleeding in liver cirrhosis. Age, treatment duration, and Child–Turcotte–Pugh class may be associated with bleeding in cirrhotic patients receiving DOACs. The risk of bleeding is not increased by DOACs in cirrhotic patients with PVT.
Authors' Contribution
Conception and design: Z. L. and X. Q.; Collection and assembly of data: Z. L., W. X., and L. C.; Data analysis and interpretation: Z. L., W. X., L. W., L. C., and X. Q.; manuscript writing: Z. L., W. X., L. W., L. C., and X. Q.; Final approval of manuscript: Z. L., W. X., L. W., L. C., W. A., F. G. R., H. L., and X. Q.; Supervision: X. Q. All authors have made an intellectual contribution to the manuscript and approved the submission.
* Co-first authors.
Publikationsverlauf
Eingereicht: 16. März 2023
Angenommen: 12. Mai 2023
Artikel online veröffentlicht:
19. Juni 2023
© 2023. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Pan J, Wang L, Gao F. et al. Epidemiology of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis. Eur J Intern Med 2022; 104: 21-32
- 2 Qi X, Ren W, Guo X, Fan D. Epidemiology of venous thromboembolism in patients with liver diseases: a systematic review and meta-analysis. Intern Emerg Med 2015; 10 (02) 205-217
- 3 Ambrosino P, Tarantino L, Di Minno G. et al. The risk of venous thromboembolism in patients with cirrhosis. A systematic review and meta-analysis. Thromb Haemost 2017; 117 (01) 139-148
- 4 An J, Shim JH, Kim SO. et al. Prevalence and prediction of coronary artery disease in patients with liver cirrhosis: a registry-based matched case-control study. Circulation 2014; 130 (16) 1353-1362
- 5 Zheng K, Yoshida EM, Tacke F, Li Y, Guo X, Qi X. Risk of stroke in liver cirrhosis: a systematic review and meta-analysis. J Clin Gastroenterol 2020; 54 (01) 96-105
- 6 Jepsen P, Tapper EB, Deleuran T. et al. Risk and outcome of venous and arterial thrombosis in patients with cirrhosis: a Danish nation-wide cohort study. Hepatology 2021; 74 (05) 2725-2734
- 7 Lee H, Choi EK, Rhee TM. et al. Cirrhosis is a risk factor for atrial fibrillation: a nationwide, population-based study. Liver Int 2017; 37 (11) 1660-1667
- 8 Stone AC, Gaborcik JW, Smetana ME. Anticoagulation considerations in liver disease. Crit Care Nurs Q 2022; 45 (02) 156-166
- 9 Lee S-R, Lee H-J, Choi E-K. et al. Direct oral anticoagulants in patients with atrial fibrillation and liver disease. J Am Coll Cardiol 2019; 73 (25) 3295-3308
- 10 Coons EM, Staubes BA, Casey AL. et al. Direct oral anticoagulants versus warfarin for treatment of thrombosis or atrial fibrillation in patients with cirrhosis: a retrospective cohort study. Ann Pharmacother 2022; 56 (05) 533-540
- 11 Davis KA, Joseph J, Nisly SA. Direct oral anticoagulants and warfarin in patients with cirrhosis: a comparison of outcomes. J Thromb Thrombolysis 2020; 50 (02) 457-461
- 12 Villa E, Cammà C, Marietta M. et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 2012; 143 (05) 1253.e4-1260.e4
- 13 Ai MH, Dong WG, Tan XP. et al. Efficacy and safety study of direct-acting oral anticoagulants for the treatment of chronic portal vein thrombosis in patients with liver cirrhosis. Eur J Gastroenterol Hepatol 2020; 32 (10) 1395-1400
- 14 Hanafy AS, Abd-Elsalam S, Dawoud MM. Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis. Vascul Pharmacol 2019; 113: 86-91
- 15 Ageno W, Gallus AS, Wittkowsky A. et al. Oral Anticoagulant Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e44S-e88S
- 16 Perzborn E, Strassburger J, Wilmen A. et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939–an oral, direct Factor Xa inhibitor. J Thromb Haemost 2005; 3 (03) 514-521
- 17 Jiménez D, Yusen RD, Ramacciotti E. Apixaban: an oral direct factor-xa inhibitor. Adv Ther 2012; 29 (03) 187-201
- 18 Reilly PA, van Ryn J, Grottke O, Glund S, Stangier J. Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects. Am J Med 2016; 129 (11S): S64-S72
- 19 Gitto S, Romanelli RG, Cellai AP. et al. Altered clot formation and lysis are associated with increased fibrinolytic activity in ascites in patients with advanced cirrhosis. Intern Emerg Med 2021; 16 (02) 339-347
- 20 Julia S, James U. Direct oral anticoagulants: a quick guide. Eur Cardiol 2017; 12 (01) 40-45
- 21 Ageno W, Beyer Westendorf J, Contino L. et al. Rivaroxaban for the treatment of noncirrhotic splanchnic vein thrombosis: an interventional prospective cohort study. Blood Adv 2022; 6 (12) 3569-3578
- 22 Ponvilawan B, Chaisidhivej N, Kinnucan JAR. Efficacy and safety of direct oral anticoagulants in treatment of splanchnic vein thrombosis in cirrhotic patients: systematic review and meta-analysis. Am J Gastroenterol 2021; 116: S525-S526
- 23 Mohan BP, Aravamudan VM, Khan SR, Ponnada S, Asokkumar R, Adler DG. Treatment response and bleeding events associated with anticoagulant therapy of portal vein thrombosis in cirrhotic patients: systematic review and meta-analysis. Ann Gastroenterol 2020; 33 (05) 521-527
- 24 Menichelli D, Ronca V, Di Rocco A, Pignatelli P, Marco Podda G. CAR. Direct oral anticoagulants and advanced liver disease: a systematic review and meta-analysis. Eur J Clin Invest 2021; 51 (03) e13397
- 25 Wang L, Guo X, Xu X. et al. Anticoagulation favors thrombus recanalization and survival in patients with liver cirrhosis and portal vein thrombosis: results of a meta-analysis. Adv Ther 2021; 38 (01) 495-520
- 26 Zhang Z, Zhao Y, Han B, Zhu Z, Sun L, Cui X. The efficacy and safety of anticoagulants in the treatment of cirrhotic portal vein thrombosis: a systematic review and meta-analysis. Clin Appl Thromb Hemost 2022; 28: 107 60296221104797
- 27 Huang ZC, Li CQ, Liu XY. et al. Efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation and liver disease: a meta-analysis and systematic review. Cardiovasc Drugs Ther 2021; 35 (06) 1205-1215
- 28 Koh JH, Liew ZH, Ng GK. et al. Efficacy and safety of direct oral anticoagulants versus vitamin K antagonist for portal vein thrombosis in cirrhosis: a systematic review and meta-analysis. Dig Liver Dis 2022; 54 (01) 56-62
- 29 Hoolwerf EW, Kraaijpoel N, Büller HR, van Es N. Direct oral anticoagulants in patients with liver cirrhosis: a systematic review. Thromb Res 2018; 170: 102-108
- 30 Chen H, Lei J, Liang S, Luo G, Deng M, Lü M. Safety and efficacy of anticoagulation in patients with cirrhosis: a meta-analysis. Can J Gastroenterol Hepatol 2021; 2021: 8859602
- 31 Ali F, Laskova A, Misra S. et al. Non-vitamin K antagonist oral anticoagulation vs standard of care for the treatment of portal venous thrombosis in cirrhotic patients; a systematic review with meta-analysis. Am J Gastroenterol 2021; 116: S544-S545
- 32 Lee ZY, Suah BH, Teo YH. et al. Comparison of the efficacy and safety of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation and concomitant liver cirrhosis: a systematic review and meta-analysis. Am J Cardiovasc Drugs 2022; 22 (02) 157-165
- 33 de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C. Baveno VII Faculty. Baveno VII - renewing consensus in portal hypertension. J Hepatol 2022; 76 (04) 959-974
- 34 Hepatobiliary Disease Study Group, Chinese Society of Gastroenterology, Chinese Medical Association. Consensus for management of portal vein thrombosis in liver cirrhosis (2020, Shanghai). J Dig Dis 2021; 22 (04) 176-186
- 35 Villa E, Bianchini M, Blasi A. et al; European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, ; European Association for the Study of the Liver. EASL clinical practice guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis. J Hepatol 2022; 76 (05) 1151-1184
- 36 O'Shea RS, Davitkov P, Ko CW. et al. AGA clinical practice guideline on the management of coagulation disorders in patients with cirrhosis. Gastroenterology 2021; 161 (05) 1615.e1-1627.e1
- 37 Sundararajan T, Chandrasekar VT, Siddiqui H. et al. Risk of major bleeding events between direct oral anticoagulants and traditional anticoagulants in patients with cirrhosis: systematic review and meta-analysis. Hepatology 2020; 72: 1149A-1150A
- 38 Kostev K, Loosen S, Roderburg C, Tanislav C. Direct oral anticoagulants versus preprohormone in patients with cirrhosis and the risk of gastrointestinal bleeding. Ann Pharmacother 2022; 56 (08) 967
- 39 Oldham M, Palkimas S, Hedrick A. Safety and efficacy of direct oral anticoagulants in patients with moderate to severe cirrhosis. Ann Pharmacother 2022; 56 (07) 782-790
- 40 Yoo SY, Kim E, Nam GB. et al. Safety of direct oral anticoagulants compared to warfarin in cirrhotic patients with atrial fibrillation. Korean J Intern Med (Korean Assoc Intern Med) 2022; 37 (03) 555-566
- 41 Yao W, Feng Y, Liu T. et al. Rivaroxaban versus low-molecular weight heparin plus warfarin prevents portal vein system thrombosis after splenectomy and pericardial devascularization: a randomized clinical trial. EXCLI J 2021; 20: 537-549
- 42 Serper M, Weinberg EM, Cohen JB, Reese PP, Taddei TH, Kaplan DE. Mortality and hepatic decompensation in patients with cirrhosis and atrial fibrillation treated with anticoagulation. Hepatology 2021; 73 (01) 219-232
- 43 Naymagon L, Tremblay D, Zubizarreta N, Moshier E, Mascarenhas J, Schiano T. Safety, efficacy, and long-term outcomes of anticoagulation in cirrhotic portal vein thrombosis. Dig Dis Sci 2021; 66 (10) 3619-3629
- 44 Ilcewicz HN, Martello JL, Piechowski K. Evaluation of the efficacy and safety of direct oral anticoagulants in the treatment of portal vein thrombosis. J Am Coll Clin Pharm 2020; 3: 147-148
- 45 Jones K, Pham C, Aguilar C, Sheth S. Retrospective review on the safety and efficacy of direct oral anticoagulants compared with warfarin in patients with cirrhosis. Fed Pract 2020; 37 (10) 479-485
- 46 Hadi Y, Naqvi S, Khan AY, Kupec J. Direct acting oral anticoagulant use is safe and effective in patients with cirrhosis. Gastroenterology 2020; 158: S-1469
- 47 Naqvi SF, Hadi Y, Ul Jannat FR. et al. Use of direct acting oral anticoagulants for pulmonary embolism and DVT in patients with cirrhosis. Chest 2020; 158: A2209
- 48 Nagaoki Y, Aikata H, Daijyo K. et al. Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis. Hepatol Res 2018; 48 (01) 51-58
- 49 Shatzel J, Chandran R, Gardiner S. et al. The safety of low molecular weight heparin, direct oral anticoagulants, & warfarin in patients with chronic liver disease; analysis of 932 patients from the RIETE database. Res Pract Thromb Haemost 2018; 2: 331
- 50 Hum J, Shatzel JJ, Jou JH, Deloughery TG. The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis. Eur J Haematol 2017; 98 (04) 393-397
- 51 Intagliata NM, Henry ZH, Maitland H. et al. Direct oral anticoagulants in cirrhosis patients pose similar risks of bleeding when compared to traditional anticoagulation. Dig Dis Sci 2016; 61 (06) 1721-1727
- 52 Jarboe L, Dadlani A, Bandikatla S, Wade R, Barve A. Drug use evaluation of direct oral anticoagulants (DOACs) in patients with advanced cirrhosis. Cureus 2022; 14 (04) e24029
- 53 Zhan C, Prabhu V, Kang SK. et al. Comparison of non-tumoral portal vein thrombosis management in cirrhotic patients: tips versus anticoagulation versus no treatment. J Clin Med 2021; 10 (11) 10
- 54 De Gottardi A, Trebicka J, Klinger C. et al; VALDIG Investigators. Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. Liver Int 2017; 37 (05) 694-699
- 55 Mort JF, Davis JPE, Mahoro G, Stotts MJ, Intagliata NM, Northup PG. Rates of bleeding and discontinuation of direct oral anticoagulants in patients with decompensated cirrhosis. Clin Gastroenterol Hepatol 2021; 19 (07) 1436-1442
- 56 Rusin G, Ząbczyk M, Natorska J, Malinowski KP, Undas A. Direct oral anticoagulants in patients with atrial fibrillation and liver cirrhosis: a single-center experience. Kardiol Pol 2021; 79 (7–8): 864-866
- 57 Werońska A, Papuga-Szela E, Broniatowska E, Undas A. Reduced–dose apixaban and dabigatran in patients with advanced liver cirrhosis and venous thromboembolism: a case series. Pol Arch Intern Med 2021; 131 (7–8): 762-765
- 58 Cisak KI, Asante D, Grill DE, Ashrani AA. Efficacy and safety of direct oral anticoagulants in patients with cirrhosis—single institution experience. Blood 2018; 132 (Suppl 1): 2525
- 59 Kunk PR, Collins H, Palkimas S, Intagliata NM, Maitland HS. Direct oral anticoagulants in patients with cirrhosis appear safe and effective. Blood 2016; 128 (22) 3827
- 60 Virstyuk N, Matkovska N, Vakalyuk I, Virstyuk O. Effect of rivaroxaban on hypercoagulopathy risk factors in liver cirrhosis patients with nonvalvular atrial fibrillation. J Hepatol 2020; 73: S767
- 61 Walker C, Aljudaibi B, Martens J. et al. Evaluation of the efficacy of apixaban use for the treatment of portal vein thrombosis in patients with cirrhosis. Hepatology 2019; 70 (01) 265
- 62 Wang M, Wang Y, Zhang G. et al. Efficacy and safety of rivaroxaban in portal vein thrombosis in patients with liver decompensated cirrhosis. J Hepatol 2020; 73: S767-S768
- 63 Nisly SA, Mihm AE, Gillette C, Davis KA, Tillett J. Safety of direct oral anticoagulants in patients with mild to moderate cirrhosis: a systematic review and meta-analysis. J Thromb Thrombolysis 2021; 52 (03) 817-827
- 64 Ng CH, Tan DJH, Nistala KRY. et al. A network meta-analysis of direct oral anticoagulants for portal vein thrombosis in cirrhosis. Hepatol Int 2021; 15 (05) 1196-1206
- 65 Lapumnuaypol K, DiMaria C, Chiasakul T. Safety of direct oral anticoagulants in patients with cirrhosis: a systematic review and meta-analysis. QJM 2019; 112 (08) 605-610
- 66 Chokesuwattanaskul R, Thongprayoon C, Bathini T. et al. Efficacy and safety of anticoagulation for atrial fibrillation in patients with cirrhosis: a systematic review and meta-analysis. Dig Liver Dis 2019; 51 (04) 489-495
- 67 Chai-Adisaksopha C, Crowther M, Isayama T, Lim W. The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood 2014; 124 (15) 2450-2458
- 68 van der Hulle T, Kooiman J, den Exter PL, Dekkers OM, Klok FA, Huisman MV. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost 2014; 12 (03) 320-328
- 69 Gunasekaran K, Rajasurya V, Devasahayam J. et al. A review of the incidence diagnosis and treatment of spontaneous hemorrhage in patients treated with direct oral anticoagulants. J Clin Med 2020; 9 (09) 9
- 70 Sardar P, Chatterjee S, Lavie CJ. et al. Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trials. Int J Cardiol 2015; 179: 279-287
- 71 Miller CS, Dorreen A, Martel M, Huynh T, Barkun AN. Risk of gastrointestinal bleeding in patients taking non-vitamin K antagonist oral anticoagulants: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2017; 15 (11) 1674.e3-1683.e3
- 72 Prelipcean CC, Fierbinteanu-Braticevici C, Drug VL, Lăcătuşu C, Mihai B, Mihai C. Liver cirrhosis–procoagulant stasis [in Romanian]. Rev Med Chir Soc Med Nat Iasi 2011; 115 (03) 678-685
- 73 Drolz A, Horvatits T, Roedl K. et al. Coagulation parameters and major bleeding in critically ill patients with cirrhosis. Hepatology 2016; 64 (02) 556-568
- 74 Ow TW, Fatourou E, Rabinowich L. et al. Prevalence of bleeding and thrombosis in critically ill patients with chronic liver disease. Thromb Haemost 2022; 122 (06) 1006-1016
- 75 Sasso R, Rockey DC. Anticoagulation therapy in patients with liver cirrhosis is associated with an increased risk of variceal hemorrhage. Am J Med 2019; 132 (06) 758-766
- 76 Mueck W, Stampfuss J, Kubitza D, Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet 2014; 53 (01) 1-16
- 77 Tran H, Joseph J, Young L. et al; Australasian Society of Thrombosis and Haemostasis. New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Intern Med J 2014; 44 (06) 525-536
- 78 Bolek T, Samoš M, Škorňová I. et al. Dabigatran levels in elderly patients with atrial fibrillation: first post-marketing experiences. Drugs Aging 2018; 35 (06) 539-544
- 79 Chen WC, Chen YH, Hsu PI. et al. Gastrointestinal hemorrhage in warfarin anticoagulated patients: incidence, risk factor, management, and outcome. BioMed Res Int 2014; 2014: 463767
- 80 Lanas-Gimeno A, Lanas A. Risk of gastrointestinal bleeding during anticoagulant treatment. Expert Opin Drug Saf 2017; 16 (06) 673-685
- 81 Di Nisio M, Valeriani E, Riva N, Schulman S, Beyer-Westendorf J, Ageno W. Anticoagulant therapy for splanchnic vein thrombosis: ISTH SSC Subcommittee Control of Anticoagulation. J Thromb Haemost 2020; 18 (07) 1562-1568
- 82 Shin KH, Kim IS, Lee HJ. et al. Thromboelastographic evaluation of coagulation in patients with liver disease. Ann Lab Med 2017; 37 (03) 204-212
- 83 Kohli R, Shingina A, New S. et al. Thromboelastography parameters are associated with cirrhosis severity. Dig Dis Sci 2019; 64 (09) 2661-2670
- 84 He Y, Yuan S, Guo X. et al. Association of thromboelastography profile with severity of liver cirrhosis and portal venous system thrombosis. BMC Gastroenterol 2021; 21 (01) 253
- 85 Lieber SR, Jiang Y, Moon A, Barritt AS. Bleeding events associated with anticoagulants and anti-platelets among a large u.s. cohort of privately-insured patients with compensated and decompensated cirrhosis. Hepatology 2019; 70 (01) 493-494
- 86 Tripodi A, Caldwell SH, Hoffman M, Trotter JF, Sanyal AJ. Review article: the prothrombin time test as a measure of bleeding risk and prognosis in liver disease. Aliment Pharmacol Ther 2007; 26 (02) 141-148
- 87 Levi M, Hovingh GK, Cannegieter SC, Vermeulen M, Büller HR, Rosendaal FR. Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based. Blood 2008; 111 (09) 4471-4476
- 88 Efird LM, Mishkin DS, Berlowitz DR. et al. Stratifying the risks of oral anticoagulation in patients with liver disease. Circ Cardiovasc Qual Outcomes 2014; 7 (03) 461-467
- 89 Qi X, De Stefano V, Li H, Dai J, Guo X, Fan D. Anticoagulation for the treatment of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis of observational studies. Eur J Intern Med 2015; 26 (01) 23-29
- 90 Loffredo L, Pastori D, Farcomeni A, Violi F. Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: a systematic review and meta-analysis. Gastroenterology 2017; 153 (02) 480.e1-487.e1